{"gene":"PDE2A","run_date":"2026-04-29T11:37:58","timeline":{"discoveries":[{"year":2009,"finding":"PDE2A splice variant 3 (PDE2A3) is targeted to synaptic membranes via dual acylation: myristoylation at Gly2 is required for membrane binding, while palmitoylation at Cys5 (and to a lesser extent Cys11) is required for plasma membrane targeting and prevents retention in ER/Golgi. Mutation of Gly2 completely solubilizes PDE2A3; mutation of palmitoylated cysteines partially solubilizes the enzyme and causes ER/Golgi accumulation.","method":"Mutagenesis of acylation sites, [3H]myristate incorporation, fluorescence microscopy in HEK293 and PC12 cells, immunofluorescence in hippocampal neurons, subcellular fractionation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro mutagenesis with direct biochemical readout plus live-cell imaging, multiple orthogonal methods in one study","pmids":["19632989"],"is_preprint":false},{"year":2005,"finding":"Crystal structure of the catalytic domain of human PDE2A at 1.7 Å resolution identified active site residues Asp811, Gln812, Ile826, and Tyr827 as determinants of inhibitor and substrate selectivity, validated by in vitro translation of active-site mutants.","method":"X-ray crystallography (1.7 Å), wheat germ in vitro translation of mutants, enzymatic activity assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus mutagenesis with enzymatic validation in single study","pmids":["15938621"],"is_preprint":false},{"year":2018,"finding":"A homozygous missense mutation (p.Asp480Gly) in the GAF-B domain of PDE2A severely decreases enzymatic activity of PDE2A and causes early-onset hereditary chorea, establishing that PDE2A enzymatic activity is required for normal striatal function.","method":"Whole-exome sequencing, functional enzymatic activity assay of mutant protein, in vitro characterization of p.Asp480Gly mutant","journal":"Movement disorders","confidence":"High","confidence_rationale":"Tier 1-2 — disease-associated mutation directly tested in enzymatic assay, linking catalytic activity to neurological phenotype","pmids":["29392776"],"is_preprint":false},{"year":2023,"finding":"In cardiomyocytes, PDE2A2 is the sole isoform expressed in neonatal rat ventricular cardiomyocytes, whereas adult cardiomyocytes express all three PDE2A isoforms (A1, A2, A3), each contributing distinctly to regulation of cAMP dynamics as detected by live-cell imaging with cAMP biosensors.","method":"CRISPR/Cas9 isoform-specific knockout via adenoviral delivery, RT-PCR isoform analysis, live-cell FRET-based cAMP biosensor imaging in primary cardiomyocytes","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 — clean isoform-specific KO with live-cell cAMP biosensor readout, single lab","pmids":["37296663"],"is_preprint":false},{"year":2020,"finding":"PDE2A knockout in mice is embryonic lethal due to liver developmental failure; loss of PDE2A increases intracellular cAMP, upregulates ICER, and downregulates anti-apoptotic Bcl2 in hepatoblasts, causing apoptosis and disruption of the liver hematopoietic niche.","method":"PDE2A knockout mouse model, morphological/cellular/molecular analyses, apoptosis assays, cAMP measurement, Western blot, in vitro hematopoietic differentiation assays","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with defined molecular pathway (cAMP→ICER→Bcl2) and cellular phenotype, single lab","pmids":["32326334"],"is_preprint":false},{"year":2025,"finding":"In striatal neurons, cGMP-stimulated PDE2A activity reduces excessive cAMP/PKA signaling driven by D1 receptor stimulation; NO donor-mediated cGMP elevation downregulates hypersensitive cAMP/PKA responses in a PDE2A-dependent manner in a 6-OHDA mouse model of Parkinson's disease.","method":"Genetically encoded cAMP and PKA biosensors in live striatal neurons, pharmacological activation/inhibition of PDE2A, 6-OHDA mouse model","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 — live-cell biosensor imaging with pharmacological dissection, single lab","pmids":["40412662"],"is_preprint":false},{"year":2024,"finding":"In PDE2A haploinsufficient mice, ~50% reduction in PDE2A protein and cGMP-hydrolyzing activity leads to disproportionate elevation of cGMP (153%) versus cAMP (16%), accompanied by compensatory upregulation of nNOS in striatal interneurons, suggesting a nNOS/NO/cGMP feedback loop compensating for reduced PDE2A-dependent cAMP hydrolysis.","method":"Heterozygous PDE2A+/- mouse model, Western blot, enzymatic activity assay, cyclic nucleotide measurement, immunohistochemistry, behavioral battery","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 — genetic model with biochemical measurements of cyclic nucleotides and compensatory pathway analysis, single lab","pmids":["39733958"],"is_preprint":false},{"year":2013,"finding":"PDE2A in antral mucous cells degrades cAMP in a cGMP-dependent manner; inhibition of PDE2 (with BAY-60-7550) mimics PKG inhibitor effects by allowing cAMP accumulation during ACh stimulation, thereby increasing Ca2+-regulated exocytosis via PKA, demonstrating PDE2A acts as a brake on cAMP-driven mucin secretion.","method":"PDE2 selective inhibitor (BAY-60-7550), cGMP/cAMP measurements in antral mucosae, Western blot and immunohistochemistry for PDE2A, exocytosis frequency assays, PKA inhibitor control","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological dissection with biochemical and functional readouts, single lab","pmids":["23449671"],"is_preprint":false},{"year":2015,"finding":"PDE2A has a presynaptic mechanism of action in hippocampal CA1: combined stimulation of adenylyl cyclase (forskolin) and soluble guanylyl cyclase (BAY 41-8543) with PDE2A inhibition (PF-999) alters paired-pulse facilitation, indicating PDE2A regulates presynaptic cAMP hydrolysis in response to cGMP changes.","method":"Paired-pulse facilitation (PPF) in acute rat hippocampal slices, selective PDE2A inhibitor PF-999, pharmacological stimulation of adenylyl and guanylyl cyclases","journal":"Synapse","confidence":"Medium","confidence_rationale":"Tier 2 — functional electrophysiological assay with pharmacological dissection showing presynaptic localization of PDE2A action, single lab","pmids":["26178667"],"is_preprint":false},{"year":1999,"finding":"PDE2A protein is selectively expressed in venous and capillary endothelial cells but not arterial endothelial cells in cardiac and renal tissue, as determined by immunocytochemistry and confirmed by in situ hybridization, suggesting a role in modulating cyclic nucleotide-mediated barrier function.","method":"Selective monoclonal antibodies, Western blot, immunocytochemistry, in situ hybridization","journal":"The journal of histochemistry and cytochemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct subcellular/tissue localization with two orthogonal methods (IHC and ISH), single lab","pmids":["10375378"],"is_preprint":false},{"year":2021,"finding":"PDE2A suppresses Wnt/β-catenin signaling in glioma stem cells by inhibiting cAMP accumulation and GSK-3β phosphorylation, thereby modulating self-renewal; PDE2A overexpression suppressed stemness of patient-derived glioma stem-like cells in vitro and in orthotopic xenograft models.","method":"PDE2A overexpression in patient-derived glioma stem-like cells, sphere formation assays, orthotopic xenograft models, GSK-3β phosphorylation and cAMP measurement, bioinformatic pathway analysis","journal":"International journal of biological sciences","confidence":"Low","confidence_rationale":"Tier 3 — overexpression with pathway readout, limited mechanistic dissection, single lab","pmids":["34512162"],"is_preprint":false},{"year":2024,"finding":"PDE2A mRNA localizes to neuronal dendrites in a non-diffusion-dependent manner consistent with active transport, and is organized into clusters potentially co-transported with other dendritically localized mRNAs, suggesting local translational regulation at synapses.","method":"Single-molecule fluorescence in situ hybridization (smFISH) in neurons, spatial distribution analysis","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 — localization data only, no functional consequence established, preprint","pmids":["bio_10.1101_2024.07.18.602927"],"is_preprint":true}],"current_model":"PDE2A is a dual-substrate cAMP/cGMP phosphodiesterase whose activity is allosterically stimulated by cGMP binding to its GAF-B domain; it is targeted to synaptic membranes via dual N-terminal acylation (myristoylation at Gly2 and palmitoylation at Cys5), acts presynaptically to regulate cAMP levels in response to cGMP signals in striatal and hippocampal neurons, and its catalytic active site residues (Asp811, Gln812, Ile826, Tyr827) determine substrate and inhibitor selectivity as established by crystal structure and mutagenesis."},"narrative":{"teleology":[{"year":1999,"claim":"Establishing where PDE2A protein is expressed at the cellular level resolved that it is selectively present in venous/capillary but not arterial endothelium, implying a tissue-specific role in cyclic nucleotide signaling at vascular barriers.","evidence":"Immunocytochemistry and in situ hybridization in cardiac and renal tissue sections","pmids":["10375378"],"confidence":"Medium","gaps":["No functional consequence of endothelial expression was demonstrated","Neuronal versus endothelial relative contributions to whole-organ PDE2A activity were not assessed"]},{"year":2005,"claim":"Solving the crystal structure of the PDE2A catalytic domain at 1.7 Å identified active-site residues (Asp811, Gln812, Ile826, Tyr827) that determine substrate and inhibitor selectivity, providing the first atomic-level explanation for PDE2A's dual cAMP/cGMP hydrolysis and a framework for selective inhibitor design.","evidence":"X-ray crystallography of catalytic domain plus mutagenesis with enzymatic activity assays using wheat germ in vitro translation","pmids":["15938621"],"confidence":"High","gaps":["Full-length structure including GAF domains was not resolved","Structural basis of cGMP-mediated allosteric activation remained unknown"]},{"year":2009,"claim":"Determining how PDE2A reaches synaptic membranes revealed a two-step lipid-modification mechanism — myristoylation at Gly2 for membrane association and palmitoylation at Cys5 for plasma membrane targeting — explaining how the enzyme is positioned to regulate local cyclic nucleotide pools at synapses.","evidence":"Mutagenesis of acylation sites, [³H]myristate incorporation, fluorescence microscopy in HEK293/PC12 cells and hippocampal neurons, subcellular fractionation","pmids":["19632989"],"confidence":"High","gaps":["Whether palmitoylation is dynamically regulated to control PDE2A redistribution was not tested","Mechanism applies to PDE2A3; membrane targeting of PDE2A1 and PDE2A2 was not addressed"]},{"year":2013,"claim":"Pharmacological dissection in gastric mucous cells demonstrated that PDE2A acts as a cGMP-dependent brake on cAMP accumulation, restraining PKA-driven Ca²⁺-regulated exocytosis — extending the enzyme's cGMP-to-cAMP cross-talk function beyond neurons.","evidence":"Selective PDE2 inhibitor BAY-60-7550, cAMP/cGMP measurements, exocytosis frequency assays in antral mucosae","pmids":["23449671"],"confidence":"Medium","gaps":["Genetic confirmation of PDE2A identity (vs. other PDE2 family members) in this tissue was not provided","Physiological source of cGMP stimulating PDE2A in vivo was not identified"]},{"year":2015,"claim":"Electrophysiological evidence in hippocampal slices showed that PDE2A inhibition alters paired-pulse facilitation only when both adenylyl and guanylyl cyclases are co-stimulated, establishing that PDE2A functions presynaptically to integrate cGMP signals into cAMP-dependent neurotransmitter release.","evidence":"Paired-pulse facilitation in acute rat hippocampal slices with selective PDE2A inhibitor PF-999 and pharmacological cyclase stimulation","pmids":["26178667"],"confidence":"Medium","gaps":["Identity of the presynaptic cGMP source (NO-sGC vs. natriuretic peptide-pGC) was not determined","Effect on specific neurotransmitter release (glutamate vs. GABA) was not resolved"]},{"year":2018,"claim":"Discovery of a homozygous GAF-B domain mutation (p.Asp480Gly) causing early-onset hereditary chorea linked PDE2A enzymatic activity to striatal circuit integrity, providing the first direct genetic evidence that PDE2A loss-of-function causes human neurological disease.","evidence":"Whole-exome sequencing in affected family, enzymatic activity assay of recombinant Asp480Gly mutant","pmids":["29392776"],"confidence":"High","gaps":["Number of families carrying PDE2A mutations was limited","Mechanism by which reduced PDE2A activity specifically disrupts striatal (chorea-relevant) versus other circuits was not defined"]},{"year":2020,"claim":"PDE2A knockout mouse lethality traced to hepatoblast apoptosis via a cAMP→ICER→Bcl2 axis revealed an essential developmental role outside the nervous system, demonstrating that PDE2A-dependent cAMP restraint is required for fetal liver organogenesis and hematopoietic niche maintenance.","evidence":"PDE2A knockout mouse, cAMP measurement, Western blot for ICER and Bcl2, apoptosis assays, in vitro hematopoietic differentiation","pmids":["32326334"],"confidence":"Medium","gaps":["Whether the hepatic phenotype is cell-autonomous was not shown by conditional knockout","Contribution of cGMP elevation versus cAMP elevation to the lethality was not separated"]},{"year":2023,"claim":"Isoform-specific CRISPR knockouts in cardiomyocytes showed that PDE2A2 is the sole neonatal isoform while adults express all three (A1, A2, A3), each with distinct contributions to cAMP compartmentalization, revealing developmental isoform switching and functional non-redundancy.","evidence":"CRISPR/Cas9 isoform-specific knockout via adenovirus in primary rat cardiomyocytes, FRET-based cAMP biosensors","pmids":["37296663"],"confidence":"Medium","gaps":["In vivo cardiac phenotype of isoform-specific loss was not assessed","Subcellular targeting determinants distinguishing PDE2A1 from PDE2A2 in cardiomyocytes were not defined"]},{"year":2024,"claim":"Haploinsufficient mice revealed that 50% reduction in PDE2A disproportionately elevates cGMP over cAMP in striatum, with compensatory nNOS upregulation, indicating a homeostatic nNOS/NO/cGMP feedback loop that partially buffers cAMP when PDE2A activity is reduced.","evidence":"PDE2A+/− mice, cyclic nucleotide quantification, Western blot, immunohistochemistry for nNOS, behavioral testing","pmids":["39733958"],"confidence":"Medium","gaps":["Whether nNOS upregulation is transcriptional or post-translational was not determined","Behavioral consequences of haploinsufficiency were mild; relevance to human heterozygous carriers is unclear"]},{"year":2025,"claim":"Live biosensor imaging in a Parkinson's disease model demonstrated that NO-driven cGMP elevation activates PDE2A to suppress D1-receptor-driven cAMP/PKA hypersensitivity in dopamine-depleted striatal neurons, positioning PDE2A as a therapeutic target for L-DOPA-induced dyskinesia.","evidence":"Genetically encoded cAMP/PKA biosensors in striatal neurons, PDE2A pharmacological inhibition, 6-OHDA mouse model","pmids":["40412662"],"confidence":"Medium","gaps":["Whether PDE2A activation can prevent dyskinesia in vivo was not tested","Direct measurement of PDE2A protein levels or activity changes after dopamine depletion was not performed"]},{"year":null,"claim":"Key unresolved questions include the full-length structure of PDE2A with GAF domains in both cGMP-free and cGMP-bound states, the identity of physiological cGMP sources driving PDE2A activation at specific synapses, and the mechanism by which PDE2A loss selectively produces striatal pathology despite broad expression.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length PDE2A structure with GAF domains resolved","Physiological cGMP source at individual synapses not identified","Cell-type-specific conditional knockouts in brain not reported"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,2,4,5,7]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[5,6,7,8]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,9]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[5,6,8]}],"complexes":[],"partners":["GSK3B","ADCY1","GUCY1A1"],"other_free_text":[]},"mechanistic_narrative":"PDE2A is a dual-substrate cyclic nucleotide phosphodiesterase that hydrolyzes both cAMP and cGMP, with its catalytic activity allosterically stimulated by cGMP binding to its GAF-B domain, enabling it to function as a molecular switch that couples cGMP signals to cAMP degradation in neurons, cardiomyocytes, and endothelial cells [PMID:15938621, PMID:29392776, PMID:26178667]. The PDE2A3 splice variant is targeted to synaptic membranes through sequential N-terminal myristoylation at Gly2 and palmitoylation at Cys5, and PDE2A acts presynaptically in hippocampal and striatal circuits to regulate cAMP/PKA signaling downstream of NO/cGMP inputs [PMID:19632989, PMID:26178667, PMID:40412662]. PDE2A knockout in mice causes embryonic lethality due to hepatoblast apoptosis driven by cAMP/ICER-mediated Bcl2 downregulation, and haploinsufficiency produces disproportionate cGMP elevation with compensatory nNOS upregulation in striatum [PMID:32326334, PMID:39733958]. A homozygous loss-of-function missense mutation (p.Asp480Gly) in the GAF-B domain causes early-onset hereditary chorea, establishing PDE2A as essential for normal striatal function [PMID:29392776]."},"prefetch_data":{"uniprot":{"accession":"O00408","full_name":"cGMP-dependent 3',5'-cyclic phosphodiesterase","aliases":["Cyclic GMP-stimulated phosphodiesterase","CGS-PDE","cGSPDE"],"length_aa":941,"mass_kda":105.7,"function":"cGMP-activated cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes (PubMed:15938621, PubMed:29392776, PubMed:9210593). Has a higher efficiency with cGMP compared to cAMP (PubMed:15938621). Plays a role in cell growth and migration (PubMed:24705027) Regulates mitochondrial cAMP levels and respiration (By similarity). Involved in the regulation of mitochondria morphology/dynamics and apoptotic cell death via local modulation of cAMP/PKA signaling in the mitochondrion, including the monitoring of local cAMP levels at the outer mitochondrial membrane and of PKA-dependent phosphorylation of DNM1L (PubMed:28463107)","subcellular_location":"Mitochondrion","url":"https://www.uniprot.org/uniprotkb/O00408/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PDE2A","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PDE2A","total_profiled":1310},"omim":[{"mim_id":"619150","title":"INTELLECTUAL DEVELOPMENTAL DISORDER WITH PAROXYSMAL DYSKINESIA OR SEIZURES; IDDPADS","url":"https://www.omim.org/entry/619150"},{"mim_id":"602658","title":"PHOSPHODIESTERASE 2A; PDE2A","url":"https://www.omim.org/entry/602658"},{"mim_id":"309550","title":"FRAGILE X MESSENGER RIBONUCLEOPROTEIN 1; FMR1","url":"https://www.omim.org/entry/309550"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":119.7},{"tissue":"lymphoid tissue","ntpm":187.7}],"url":"https://www.proteinatlas.org/search/PDE2A"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O00408","domains":[{"cath_id":"3.30.450.40","chopping":"44-194","consensus_level":"high","plddt":82.2422,"start":44,"end":194},{"cath_id":"3.30.450.40","chopping":"237-386","consensus_level":"high","plddt":90.4631,"start":237,"end":386},{"cath_id":"3.30.450.40","chopping":"406-556","consensus_level":"high","plddt":86.2604,"start":406,"end":556},{"cath_id":"1.10.1300.10","chopping":"576-594_614-790","consensus_level":"medium","plddt":93.9113,"start":576,"end":790},{"cath_id":"-","chopping":"814-917","consensus_level":"medium","plddt":88.049,"start":814,"end":917}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00408","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00408-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00408-F1-predicted_aligned_error_v6.png","plddt_mean":83.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PDE2A","jax_strain_url":"https://www.jax.org/strain/search?query=PDE2A"},"sequence":{"accession":"O00408","fasta_url":"https://rest.uniprot.org/uniprotkb/O00408.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00408/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00408"}},"corpus_meta":[{"pmid":"10375378","id":"PMC_10375378","title":"Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells.","date":"1999","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/10375378","citation_count":55,"is_preprint":false},{"pmid":"29392776","id":"PMC_29392776","title":"A homozygous loss-of-function mutation in PDE2A associated to early-onset hereditary chorea.","date":"2018","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/29392776","citation_count":51,"is_preprint":false},{"pmid":"19632989","id":"PMC_19632989","title":"Dual acylation of PDE2A splice variant 3: targeting to synaptic membranes.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19632989","citation_count":49,"is_preprint":false},{"pmid":"15938621","id":"PMC_15938621","title":"Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.","date":"2005","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15938621","citation_count":44,"is_preprint":false},{"pmid":"28165743","id":"PMC_28165743","title":"Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders.","date":"2017","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28165743","citation_count":31,"is_preprint":false},{"pmid":"26178667","id":"PMC_26178667","title":"Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus.","date":"2015","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/26178667","citation_count":30,"is_preprint":false},{"pmid":"34512162","id":"PMC_34512162","title":"miR-139/PDE2A-Notch1 feedback circuit represses stemness of gliomas by inhibiting Wnt/β-catenin signaling.","date":"2021","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34512162","citation_count":29,"is_preprint":false},{"pmid":"32119913","id":"PMC_32119913","title":"Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease.","date":"2020","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/32119913","citation_count":26,"is_preprint":false},{"pmid":"27321640","id":"PMC_27321640","title":"Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).","date":"2016","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/27321640","citation_count":21,"is_preprint":false},{"pmid":"19049345","id":"PMC_19049345","title":"A novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors.","date":"2009","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/19049345","citation_count":19,"is_preprint":false},{"pmid":"30651902","id":"PMC_30651902","title":"Low-Concentration Oxygen/Ozone Treatment Attenuated Radiculitis and Mechanical Allodynia via PDE2A-cAMP/cGMP-NF-κB/p65 Signaling in Chronic Radiculitis Rats.","date":"2018","source":"Pain research & management","url":"https://pubmed.ncbi.nlm.nih.gov/30651902","citation_count":19,"is_preprint":false},{"pmid":"36163142","id":"PMC_36163142","title":"PDE2A Inhibition Enhances Axonal Sprouting, Functional Connectivity, and Recovery after Stroke.","date":"2022","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36163142","citation_count":12,"is_preprint":false},{"pmid":"32326334","id":"PMC_32326334","title":"PDE2A Is Indispensable for Mouse Liver Development and Hematopoiesis.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32326334","citation_count":11,"is_preprint":false},{"pmid":"37317634","id":"PMC_37317634","title":"A homozygous founder variant in PDE2A causes paroxysmal dyskinesia with intellectual disability.","date":"2023","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37317634","citation_count":9,"is_preprint":false},{"pmid":"23449671","id":"PMC_23449671","title":"A PKG inhibitor increases Ca(2+)-regulated exocytosis in guinea pig antral mucous cells: cAMP accumulation via PDE2A inhibition.","date":"2013","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23449671","citation_count":6,"is_preprint":false},{"pmid":"33729823","id":"PMC_33729823","title":"Shear stress-induced MMP1 and PDE2A expressions in coronary atherosclerosis.","date":"2021","source":"Bratislavske lekarske listy","url":"https://pubmed.ncbi.nlm.nih.gov/33729823","citation_count":4,"is_preprint":false},{"pmid":"37296663","id":"PMC_37296663","title":"CRISPR/Cas9 Knock-Out in Primary Neonatal and Adult Cardiomyocytes Reveals Distinct cAMP Dynamics Regulation by Various PDE2A and PDE3A Isoforms.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37296663","citation_count":3,"is_preprint":false},{"pmid":"36297384","id":"PMC_36297384","title":"Radiosynthesis and Preclinical Evaluation of an 18F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A).","date":"2022","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36297384","citation_count":3,"is_preprint":false},{"pmid":"27966018","id":"PMC_27966018","title":"Identification of lead BAY60-7550 analogues as potential inhibitors that utilize the hydrophobic groove in PDE2A: a molecular dynamics simulation study.","date":"2016","source":"Journal of molecular modeling","url":"https://pubmed.ncbi.nlm.nih.gov/27966018","citation_count":3,"is_preprint":false},{"pmid":"39733958","id":"PMC_39733958","title":"Haploinsufficiency of PDE2A causes in mice increased exploratory behavior associated with upregulation of neural nitric oxide synthase in the striatum.","date":"2024","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/39733958","citation_count":1,"is_preprint":false},{"pmid":"40412662","id":"PMC_40412662","title":"Activation of PDE2A moderates pathologically high cAMP/PKA responses to dopamine in dyskinetic mice.","date":"2025","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/40412662","citation_count":0,"is_preprint":false},{"pmid":"41988816","id":"PMC_41988816","title":"Anacardic Acid Inhibits Pde2a to Enhance Colonic Epithelial Barrier Integrity in the Improvement of Diabetic Cardiomyopathy.","date":"2026","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/41988816","citation_count":0,"is_preprint":false},{"pmid":"41878336","id":"PMC_41878336","title":"Metabolic profiling of the TME uncovers the contrasting impacts of CKMT2 and PDE2A in CRC progression and therapeutic response.","date":"2026","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41878336","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.07.18.602927","title":"Characterizing the Spatial Distribution of Dendritic RNA at Single Molecule Resolution","date":"2024-07-19","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.18.602927","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14082,"output_tokens":2990,"usd":0.043548},"stage2":{"model":"claude-opus-4-6","input_tokens":6360,"output_tokens":2912,"usd":0.1569},"total_usd":0.200448,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"PDE2A splice variant 3 (PDE2A3) is targeted to synaptic membranes via dual acylation: myristoylation at Gly2 is required for membrane binding, while palmitoylation at Cys5 (and to a lesser extent Cys11) is required for plasma membrane targeting and prevents retention in ER/Golgi. Mutation of Gly2 completely solubilizes PDE2A3; mutation of palmitoylated cysteines partially solubilizes the enzyme and causes ER/Golgi accumulation.\",\n      \"method\": \"Mutagenesis of acylation sites, [3H]myristate incorporation, fluorescence microscopy in HEK293 and PC12 cells, immunofluorescence in hippocampal neurons, subcellular fractionation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro mutagenesis with direct biochemical readout plus live-cell imaging, multiple orthogonal methods in one study\",\n      \"pmids\": [\"19632989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structure of the catalytic domain of human PDE2A at 1.7 Å resolution identified active site residues Asp811, Gln812, Ile826, and Tyr827 as determinants of inhibitor and substrate selectivity, validated by in vitro translation of active-site mutants.\",\n      \"method\": \"X-ray crystallography (1.7 Å), wheat germ in vitro translation of mutants, enzymatic activity assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus mutagenesis with enzymatic validation in single study\",\n      \"pmids\": [\"15938621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A homozygous missense mutation (p.Asp480Gly) in the GAF-B domain of PDE2A severely decreases enzymatic activity of PDE2A and causes early-onset hereditary chorea, establishing that PDE2A enzymatic activity is required for normal striatal function.\",\n      \"method\": \"Whole-exome sequencing, functional enzymatic activity assay of mutant protein, in vitro characterization of p.Asp480Gly mutant\",\n      \"journal\": \"Movement disorders\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — disease-associated mutation directly tested in enzymatic assay, linking catalytic activity to neurological phenotype\",\n      \"pmids\": [\"29392776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In cardiomyocytes, PDE2A2 is the sole isoform expressed in neonatal rat ventricular cardiomyocytes, whereas adult cardiomyocytes express all three PDE2A isoforms (A1, A2, A3), each contributing distinctly to regulation of cAMP dynamics as detected by live-cell imaging with cAMP biosensors.\",\n      \"method\": \"CRISPR/Cas9 isoform-specific knockout via adenoviral delivery, RT-PCR isoform analysis, live-cell FRET-based cAMP biosensor imaging in primary cardiomyocytes\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean isoform-specific KO with live-cell cAMP biosensor readout, single lab\",\n      \"pmids\": [\"37296663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PDE2A knockout in mice is embryonic lethal due to liver developmental failure; loss of PDE2A increases intracellular cAMP, upregulates ICER, and downregulates anti-apoptotic Bcl2 in hepatoblasts, causing apoptosis and disruption of the liver hematopoietic niche.\",\n      \"method\": \"PDE2A knockout mouse model, morphological/cellular/molecular analyses, apoptosis assays, cAMP measurement, Western blot, in vitro hematopoietic differentiation assays\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined molecular pathway (cAMP→ICER→Bcl2) and cellular phenotype, single lab\",\n      \"pmids\": [\"32326334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In striatal neurons, cGMP-stimulated PDE2A activity reduces excessive cAMP/PKA signaling driven by D1 receptor stimulation; NO donor-mediated cGMP elevation downregulates hypersensitive cAMP/PKA responses in a PDE2A-dependent manner in a 6-OHDA mouse model of Parkinson's disease.\",\n      \"method\": \"Genetically encoded cAMP and PKA biosensors in live striatal neurons, pharmacological activation/inhibition of PDE2A, 6-OHDA mouse model\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — live-cell biosensor imaging with pharmacological dissection, single lab\",\n      \"pmids\": [\"40412662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In PDE2A haploinsufficient mice, ~50% reduction in PDE2A protein and cGMP-hydrolyzing activity leads to disproportionate elevation of cGMP (153%) versus cAMP (16%), accompanied by compensatory upregulation of nNOS in striatal interneurons, suggesting a nNOS/NO/cGMP feedback loop compensating for reduced PDE2A-dependent cAMP hydrolysis.\",\n      \"method\": \"Heterozygous PDE2A+/- mouse model, Western blot, enzymatic activity assay, cyclic nucleotide measurement, immunohistochemistry, behavioral battery\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic model with biochemical measurements of cyclic nucleotides and compensatory pathway analysis, single lab\",\n      \"pmids\": [\"39733958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PDE2A in antral mucous cells degrades cAMP in a cGMP-dependent manner; inhibition of PDE2 (with BAY-60-7550) mimics PKG inhibitor effects by allowing cAMP accumulation during ACh stimulation, thereby increasing Ca2+-regulated exocytosis via PKA, demonstrating PDE2A acts as a brake on cAMP-driven mucin secretion.\",\n      \"method\": \"PDE2 selective inhibitor (BAY-60-7550), cGMP/cAMP measurements in antral mucosae, Western blot and immunohistochemistry for PDE2A, exocytosis frequency assays, PKA inhibitor control\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection with biochemical and functional readouts, single lab\",\n      \"pmids\": [\"23449671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PDE2A has a presynaptic mechanism of action in hippocampal CA1: combined stimulation of adenylyl cyclase (forskolin) and soluble guanylyl cyclase (BAY 41-8543) with PDE2A inhibition (PF-999) alters paired-pulse facilitation, indicating PDE2A regulates presynaptic cAMP hydrolysis in response to cGMP changes.\",\n      \"method\": \"Paired-pulse facilitation (PPF) in acute rat hippocampal slices, selective PDE2A inhibitor PF-999, pharmacological stimulation of adenylyl and guanylyl cyclases\",\n      \"journal\": \"Synapse\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional electrophysiological assay with pharmacological dissection showing presynaptic localization of PDE2A action, single lab\",\n      \"pmids\": [\"26178667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PDE2A protein is selectively expressed in venous and capillary endothelial cells but not arterial endothelial cells in cardiac and renal tissue, as determined by immunocytochemistry and confirmed by in situ hybridization, suggesting a role in modulating cyclic nucleotide-mediated barrier function.\",\n      \"method\": \"Selective monoclonal antibodies, Western blot, immunocytochemistry, in situ hybridization\",\n      \"journal\": \"The journal of histochemistry and cytochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct subcellular/tissue localization with two orthogonal methods (IHC and ISH), single lab\",\n      \"pmids\": [\"10375378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PDE2A suppresses Wnt/β-catenin signaling in glioma stem cells by inhibiting cAMP accumulation and GSK-3β phosphorylation, thereby modulating self-renewal; PDE2A overexpression suppressed stemness of patient-derived glioma stem-like cells in vitro and in orthotopic xenograft models.\",\n      \"method\": \"PDE2A overexpression in patient-derived glioma stem-like cells, sphere formation assays, orthotopic xenograft models, GSK-3β phosphorylation and cAMP measurement, bioinformatic pathway analysis\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — overexpression with pathway readout, limited mechanistic dissection, single lab\",\n      \"pmids\": [\"34512162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PDE2A mRNA localizes to neuronal dendrites in a non-diffusion-dependent manner consistent with active transport, and is organized into clusters potentially co-transported with other dendritically localized mRNAs, suggesting local translational regulation at synapses.\",\n      \"method\": \"Single-molecule fluorescence in situ hybridization (smFISH) in neurons, spatial distribution analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — localization data only, no functional consequence established, preprint\",\n      \"pmids\": [\"bio_10.1101_2024.07.18.602927\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"PDE2A is a dual-substrate cAMP/cGMP phosphodiesterase whose activity is allosterically stimulated by cGMP binding to its GAF-B domain; it is targeted to synaptic membranes via dual N-terminal acylation (myristoylation at Gly2 and palmitoylation at Cys5), acts presynaptically to regulate cAMP levels in response to cGMP signals in striatal and hippocampal neurons, and its catalytic active site residues (Asp811, Gln812, Ile826, Tyr827) determine substrate and inhibitor selectivity as established by crystal structure and mutagenesis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PDE2A is a dual-substrate cyclic nucleotide phosphodiesterase that hydrolyzes both cAMP and cGMP, with its catalytic activity allosterically stimulated by cGMP binding to its GAF-B domain, enabling it to function as a molecular switch that couples cGMP signals to cAMP degradation in neurons, cardiomyocytes, and endothelial cells [PMID:15938621, PMID:29392776, PMID:26178667]. The PDE2A3 splice variant is targeted to synaptic membranes through sequential N-terminal myristoylation at Gly2 and palmitoylation at Cys5, and PDE2A acts presynaptically in hippocampal and striatal circuits to regulate cAMP/PKA signaling downstream of NO/cGMP inputs [PMID:19632989, PMID:26178667, PMID:40412662]. PDE2A knockout in mice causes embryonic lethality due to hepatoblast apoptosis driven by cAMP/ICER-mediated Bcl2 downregulation, and haploinsufficiency produces disproportionate cGMP elevation with compensatory nNOS upregulation in striatum [PMID:32326334, PMID:39733958]. A homozygous loss-of-function missense mutation (p.Asp480Gly) in the GAF-B domain causes early-onset hereditary chorea, establishing PDE2A as essential for normal striatal function [PMID:29392776].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing where PDE2A protein is expressed at the cellular level resolved that it is selectively present in venous/capillary but not arterial endothelium, implying a tissue-specific role in cyclic nucleotide signaling at vascular barriers.\",\n      \"evidence\": \"Immunocytochemistry and in situ hybridization in cardiac and renal tissue sections\",\n      \"pmids\": [\"10375378\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional consequence of endothelial expression was demonstrated\", \"Neuronal versus endothelial relative contributions to whole-organ PDE2A activity were not assessed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Solving the crystal structure of the PDE2A catalytic domain at 1.7 Å identified active-site residues (Asp811, Gln812, Ile826, Tyr827) that determine substrate and inhibitor selectivity, providing the first atomic-level explanation for PDE2A's dual cAMP/cGMP hydrolysis and a framework for selective inhibitor design.\",\n      \"evidence\": \"X-ray crystallography of catalytic domain plus mutagenesis with enzymatic activity assays using wheat germ in vitro translation\",\n      \"pmids\": [\"15938621\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length structure including GAF domains was not resolved\", \"Structural basis of cGMP-mediated allosteric activation remained unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Determining how PDE2A reaches synaptic membranes revealed a two-step lipid-modification mechanism — myristoylation at Gly2 for membrane association and palmitoylation at Cys5 for plasma membrane targeting — explaining how the enzyme is positioned to regulate local cyclic nucleotide pools at synapses.\",\n      \"evidence\": \"Mutagenesis of acylation sites, [³H]myristate incorporation, fluorescence microscopy in HEK293/PC12 cells and hippocampal neurons, subcellular fractionation\",\n      \"pmids\": [\"19632989\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether palmitoylation is dynamically regulated to control PDE2A redistribution was not tested\", \"Mechanism applies to PDE2A3; membrane targeting of PDE2A1 and PDE2A2 was not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Pharmacological dissection in gastric mucous cells demonstrated that PDE2A acts as a cGMP-dependent brake on cAMP accumulation, restraining PKA-driven Ca²⁺-regulated exocytosis — extending the enzyme's cGMP-to-cAMP cross-talk function beyond neurons.\",\n      \"evidence\": \"Selective PDE2 inhibitor BAY-60-7550, cAMP/cGMP measurements, exocytosis frequency assays in antral mucosae\",\n      \"pmids\": [\"23449671\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genetic confirmation of PDE2A identity (vs. other PDE2 family members) in this tissue was not provided\", \"Physiological source of cGMP stimulating PDE2A in vivo was not identified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Electrophysiological evidence in hippocampal slices showed that PDE2A inhibition alters paired-pulse facilitation only when both adenylyl and guanylyl cyclases are co-stimulated, establishing that PDE2A functions presynaptically to integrate cGMP signals into cAMP-dependent neurotransmitter release.\",\n      \"evidence\": \"Paired-pulse facilitation in acute rat hippocampal slices with selective PDE2A inhibitor PF-999 and pharmacological cyclase stimulation\",\n      \"pmids\": [\"26178667\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the presynaptic cGMP source (NO-sGC vs. natriuretic peptide-pGC) was not determined\", \"Effect on specific neurotransmitter release (glutamate vs. GABA) was not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Discovery of a homozygous GAF-B domain mutation (p.Asp480Gly) causing early-onset hereditary chorea linked PDE2A enzymatic activity to striatal circuit integrity, providing the first direct genetic evidence that PDE2A loss-of-function causes human neurological disease.\",\n      \"evidence\": \"Whole-exome sequencing in affected family, enzymatic activity assay of recombinant Asp480Gly mutant\",\n      \"pmids\": [\"29392776\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Number of families carrying PDE2A mutations was limited\", \"Mechanism by which reduced PDE2A activity specifically disrupts striatal (chorea-relevant) versus other circuits was not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"PDE2A knockout mouse lethality traced to hepatoblast apoptosis via a cAMP→ICER→Bcl2 axis revealed an essential developmental role outside the nervous system, demonstrating that PDE2A-dependent cAMP restraint is required for fetal liver organogenesis and hematopoietic niche maintenance.\",\n      \"evidence\": \"PDE2A knockout mouse, cAMP measurement, Western blot for ICER and Bcl2, apoptosis assays, in vitro hematopoietic differentiation\",\n      \"pmids\": [\"32326334\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the hepatic phenotype is cell-autonomous was not shown by conditional knockout\", \"Contribution of cGMP elevation versus cAMP elevation to the lethality was not separated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Isoform-specific CRISPR knockouts in cardiomyocytes showed that PDE2A2 is the sole neonatal isoform while adults express all three (A1, A2, A3), each with distinct contributions to cAMP compartmentalization, revealing developmental isoform switching and functional non-redundancy.\",\n      \"evidence\": \"CRISPR/Cas9 isoform-specific knockout via adenovirus in primary rat cardiomyocytes, FRET-based cAMP biosensors\",\n      \"pmids\": [\"37296663\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo cardiac phenotype of isoform-specific loss was not assessed\", \"Subcellular targeting determinants distinguishing PDE2A1 from PDE2A2 in cardiomyocytes were not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Haploinsufficient mice revealed that 50% reduction in PDE2A disproportionately elevates cGMP over cAMP in striatum, with compensatory nNOS upregulation, indicating a homeostatic nNOS/NO/cGMP feedback loop that partially buffers cAMP when PDE2A activity is reduced.\",\n      \"evidence\": \"PDE2A+/− mice, cyclic nucleotide quantification, Western blot, immunohistochemistry for nNOS, behavioral testing\",\n      \"pmids\": [\"39733958\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether nNOS upregulation is transcriptional or post-translational was not determined\", \"Behavioral consequences of haploinsufficiency were mild; relevance to human heterozygous carriers is unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Live biosensor imaging in a Parkinson's disease model demonstrated that NO-driven cGMP elevation activates PDE2A to suppress D1-receptor-driven cAMP/PKA hypersensitivity in dopamine-depleted striatal neurons, positioning PDE2A as a therapeutic target for L-DOPA-induced dyskinesia.\",\n      \"evidence\": \"Genetically encoded cAMP/PKA biosensors in striatal neurons, PDE2A pharmacological inhibition, 6-OHDA mouse model\",\n      \"pmids\": [\"40412662\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PDE2A activation can prevent dyskinesia in vivo was not tested\", \"Direct measurement of PDE2A protein levels or activity changes after dopamine depletion was not performed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full-length structure of PDE2A with GAF domains in both cGMP-free and cGMP-bound states, the identity of physiological cGMP sources driving PDE2A activation at specific synapses, and the mechanism by which PDE2A loss selectively produces striatal pathology despite broad expression.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length PDE2A structure with GAF domains resolved\", \"Physiological cGMP source at individual synapses not identified\", \"Cell-type-specific conditional knockouts in brain not reported\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 2, 4, 5, 7]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [5, 6, 7, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 9]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [5, 7, 8]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [5, 6, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GSK3B\",\n      \"ADCY1\",\n      \"GUCY1A1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}